SubsidieMeestersReprogramming of Tumor Stroma to Enhance Cancer Immunotherapy
This project aims to enhance cancer immunotherapy effectiveness in solid tumors by targeting tumor-activated mesenchymal stromal cells within the immunosuppressive tumor microenvironment.
Projectdetails
Introduction
Cancer immunotherapies have shown impressive success in cancer treatment. However, these therapies are limited to certain types of cancers, and the success rate is still low.
Challenges in Solid Tumors
In particular, certain types of solid tumors containing an abundant stroma, which represent a majority of epithelial-derived cancer, respond very poorly to immunotherapies. A major challenge for the development of novel cancer immunotherapies in these tumors is represented by the tumor microenvironment (TME).
Characteristics of the TME
The TME is a highly hypoxic and immunosuppressive environment that prevents proper tumor infiltration and functioning of effector immune cells. Recent discoveries have identified tumor-activated mesenchymal stromal cells (MSCs) developing within the TME, showing that they represent a major brake for efficient antitumor immunity in solid tumors.
Project Objectives
In this project, we will investigate the potential of a novel approach and therapeutic avenue to:
- Target specific populations of MSCs within the TME.
- Determine the synergistic effect with immunotherapies to improve treatment efficacy in solid tumors.
Long-term Goals
In the long term, this project aims at overcoming a major barrier in utilizing cancer immunotherapies in solid tumors.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-6-2024 |
| Einddatum | 30-11-2025 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- INSTITUT PASTEURpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Elucidating the networks of immune stromal connections by Perturbation of Immunity in Cancer - towards developing novel therapeutic strategiesThis project aims to map immune and stromal cell interactions in the tumor microenvironment to develop targeted therapies that enhance immunotherapy efficacy against cancer. | ERC Starting... | € 1.500.000 | 2025 | Details |
Live biotherapeutics to potentiate cancer immunotherapyThe project aims to enhance immunotherapy efficacy by using engineered live biotherapeutics to normalize tumor stiffness and improve blood flow in colorectal and breast cancer models. | ERC Proof of... | € 150.000 | 2023 | Details |
Targeting eicosanoid metabolism to overcome tumor immunosuppressionThis project aims to enhance cancer immunotherapy efficacy by targeting HPGDS in tumor-associated macrophages to reshape the immunosuppressive tumor microenvironment and improve patient outcomes. | ERC Proof of... | € 150.000 | 2024 | Details |
Developing novel single-cell technologies to model and perturb intra-tumor interactions and signaling – an innovation program for the next generation of immunotherapiesThe TROJAN-Cell project aims to engineer immune responses against tumors by understanding immune-suppressive mechanisms in the tumor microenvironment using advanced single-cell technologies. | ERC Advanced... | € 2.500.000 | 2022 | Details |
Developing the next generation of cis-targeting macrophage-T cell cancer immunotherapiesThis project aims to develop dual-modulatory agents to enhance anti-tumor immune responses in cancer immunotherapy while minimizing side effects, seeking proof-of-concept validation. | ERC Proof of... | € 150.000 | 2023 | Details |
Elucidating the networks of immune stromal connections by Perturbation of Immunity in Cancer - towards developing novel therapeutic strategies
This project aims to map immune and stromal cell interactions in the tumor microenvironment to develop targeted therapies that enhance immunotherapy efficacy against cancer.
Live biotherapeutics to potentiate cancer immunotherapy
The project aims to enhance immunotherapy efficacy by using engineered live biotherapeutics to normalize tumor stiffness and improve blood flow in colorectal and breast cancer models.
Targeting eicosanoid metabolism to overcome tumor immunosuppression
This project aims to enhance cancer immunotherapy efficacy by targeting HPGDS in tumor-associated macrophages to reshape the immunosuppressive tumor microenvironment and improve patient outcomes.
Developing novel single-cell technologies to model and perturb intra-tumor interactions and signaling – an innovation program for the next generation of immunotherapies
The TROJAN-Cell project aims to engineer immune responses against tumors by understanding immune-suppressive mechanisms in the tumor microenvironment using advanced single-cell technologies.
Developing the next generation of cis-targeting macrophage-T cell cancer immunotherapies
This project aims to develop dual-modulatory agents to enhance anti-tumor immune responses in cancer immunotherapy while minimizing side effects, seeking proof-of-concept validation.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineeringThe project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer. | EIC Accelerator | € 2.434.790 | 2025 | Details |
Functional chemical reprogramming of cancer cells to induce antitumor immunityThe RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments. | EIC Pathfinder | € 2.966.695 | 2024 | Details |
Breakthrough Neoantigen-specific Tumor-Infiltrating Lymphocyte Therapies Through Novel Dendritic Cell ReprogrammingThe Repro-TIL project aims to enhance tumor-reactive TIL expansion for more effective immunotherapy in solid tumors, paving the way for improved treatment outcomes and commercialization. | EIC Transition | € 2.480.367 | 2025 | Details |
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering
The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.
Functional chemical reprogramming of cancer cells to induce antitumor immunity
The RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments.
Breakthrough Neoantigen-specific Tumor-Infiltrating Lymphocyte Therapies Through Novel Dendritic Cell Reprogramming
The Repro-TIL project aims to enhance tumor-reactive TIL expansion for more effective immunotherapy in solid tumors, paving the way for improved treatment outcomes and commercialization.